These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30512144)

  • 1. [Not Available].
    Strandberg K
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512144
    [No Abstract]   [Full Text] [Related]  

  • 2. Measuring Direct Oral Anticoagulants.
    Gosselin RC; Douxfils J
    Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
    Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
    Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
    Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
    JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring options and reversal agents for oral anticoagulants].
    Thorup SB; Husted SE; Vang ML
    Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory monitoring of the non-vitamin K oral anticoagulants.
    Blann AD; Lip GY
    J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
    [No Abstract]   [Full Text] [Related]  

  • 9. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
    Adcock DM; Gosselin R
    Thromb Res; 2015 Jul; 136(1):7-12. PubMed ID: 25981138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ; Chan NC; Eikelboom JW
    Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Large studies of NOAC shows good and safe stroke protection].
    Hijazi Z; Oldgren J
    Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
    [No Abstract]   [Full Text] [Related]  

  • 13. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
    Tripodi A; Chantarangkul V; Legnani C; Testa S; Tosetto A
    J Thromb Haemost; 2018 Mar; 16(3):565-570. PubMed ID: 29322630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
    Lindahl S; Dyrkorn R; Spigset O; Hegstad S
    Ther Drug Monit; 2018 Jun; 40(3):369-376. PubMed ID: 29578938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
    Ebner M; Peter A; Spencer C; Härtig F; Birschmann I; Kuhn J; Wolf M; Winter N; Russo F; Zuern CS; Blumenstock G; Ziemann U; Poli S
    Stroke; 2015 Oct; 46(10):2741-7. PubMed ID: 26272385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of direct oral anticoagulant assay use in clinical practice.
    Gu TM; Garcia DA; Sabath DE
    J Thromb Thrombolysis; 2019 Apr; 47(3):403-408. PubMed ID: 30600427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of apixaban concentrations in real‑world clinical and laboratory settings: the first Polish experience.
    Góralczyk T; Papuga-Szela E; Żuk J; Undas A
    Pol Arch Intern Med; 2018 May; 128(5):324-326. PubMed ID: 29768395
    [No Abstract]   [Full Text] [Related]  

  • 19. Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays.
    Kuhn J; Gripp T; Flieder T; Hammerschmidt A; Hendig D; Faust I; Knabbe C; Birschmann I
    Clin Chim Acta; 2018 Nov; 486():347-356. PubMed ID: 30114406
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.
    Jain N; Reilly RF
    Clin J Am Soc Nephrol; 2019 Feb; 14(2):278-287. PubMed ID: 29802125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.